Gapping up
News:
- RRD +4% (receives non-binding proposal for $11.00 per share)
- IMVT +1.2% (to initiate Phase 3 study for batoclimab in 1H22)
- VSCO +0.8% (continued strength)
Gapping up
News:
- RRD +4% (receives non-binding proposal for $11.00 per share)
- IMVT +1.2% (to initiate Phase 3 study for batoclimab in 1H22)
- VSCO +0.8% (continued strength)